Saturday, October 31, 2026

U.S. 10-Year Yield Climbs to 4.30%, Repricing Growth Stocks Globally as JPMorgan Surges 129% in Three Years

The U.S. 10-year Treasury yield rose to 4.30%, tightening financial conditions across global markets. High-multiple technology stocks face renewed valuation pressure while banks benefit from wider net interest margins. The rate move is extending into mortgage markets, with the 30-year benchmark climbing from 6.0% to 6.3%.

LM Salvado
LM Salvado

May 18, 2026

U.S. 10-Year Yield Climbs to 4.30%, Repricing Growth Stocks Globally as JPMorgan Surges 129% in Three Years
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The U.S. 10-year Treasury yield climbed from 3.97% to 4.30%, resetting the global risk-free benchmark and squeezing valuations on growth-oriented equities worldwide.1

The effect is sharpest in technology. Okta, a U.S.-listed cybersecurity firm, has fallen 65.3% over five years and 35% over the past year — despite a 22.9% monthly rebound.1 Higher yields lift the discount rate applied to future cash flows, compressing present values for SaaS and software businesses that trade on long-duration earnings.

The same dynamic is felt in tech-heavy markets globally. Indices in South Korea, Taiwan, and Germany — all with significant semiconductor and software exposure — have faced parallel pressure as dollar yields rise and capital reprices risk accordingly.

Banks are the mirror image. JPMorgan Chase returned 129.1% over three years and 107.7% over five years.1 Rising rates widen net interest margins — the spread between loan income and deposit costs — boosting profitability without operational change. European and Asian banks with large loan books have seen similar tailwinds in their domestic markets.

The 30-year U.S. mortgage benchmark moved from 6.0% to 6.3%, signalling that rate pressure is now flowing into housing and consumer credit.1 For emerging economies carrying dollar-denominated debt, a sustained high-yield environment in the U.S. also tightens external financing conditions.

At 4.30%, the U.S. risk-free rate competes directly with equity risk premiums. Technology stocks trading at 10x or more forward revenue face the steepest corrections when discount rates rise. Banks, energy companies, and value sectors do not.

The pattern mirrors the 2022 Federal Reserve tightening cycle, which sent global growth stocks down 40–70%. The current move is narrower but directionally identical. Until the 10-year yield retreats well below 4%, the valuation gap between growth and value is unlikely to close.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com